Please use this identifier to cite or link to this item:
Title: 92-gene molecular profiling in identification of cancer origin: A retrospective study in Chinese population and performance within different subgroups
Authors: Wu F.
Huang D.
Wang L.
Xu Q.
Liu F. 
Ye X.
Meng X.
Du X. 
Keywords: adrenal cancer
bladder cancer
breast cancer
cancer diagnosis
cancer grading
controlled study
diagnostic accuracy
diagnostic procedure
diagnostic test accuracy study
endometrium cancer
gallbladder cancer
gastrointestinal stromal tumor
gene expression profiling
germ cell tumor
head and neck cancer
human cell
human tissue
intestine cancer
kidney cancer
laser capture microdissection
liver cancer
lung cancer
major clinical study
malignant neoplastic disease
neuroendocrine tumor
ovary cancer
pancreas cancer
performance measurement system
population research
predictive value
primary tumor
prostate cancer
reference value
retrospective study
scoring system
sensitivity and specificity
skin cancer
thyroid cancer
Asian Continental Ancestry Group
Gene Expression Profiling
Retrospective Studies
Sensitivity and Specificity
Issue Date: 2012
Publisher: Public Library of Science
Citation: Wu F., Huang D., Wang L., Xu Q., Liu F., Ye X., Meng X., Du X. (2012). 92-gene molecular profiling in identification of cancer origin: A retrospective study in Chinese population and performance within different subgroups. PLoS ONE 7 (6) : e39320. ScholarBank@NUS Repository.
Abstract: Background: After cancer diagnosis, therapy for the patient is largely dependent on the tumor origin, especially when a metastatic tumor is being treated. However, cases such as untypical metastasis, poorly differentiated tumors or even a limited number of tumor cells may lead to challenges in identifying the origin. Moreover, approximately 3% to 5% of total solid tumor patients will not have to have their tumor origin identified in their lifetime. The THEROS CancerTYPE ID® is designed for identifying the tumor origin with an objective, rapid and standardized procedure. Methodology and Principal Findings: This is a blinded retrospective study to evaluate performance of the THEROS CancerTYPE ID® in a Chinese population. In total, 184 formalin-fixed paraffin-embedded (FFPE) samples of 23 tumor origins were collected from the tissue bank of Fudan University Shanghai Cancer Center (FDUSCC). A standard tumor cell enrichment process was used, and the prediction results were compared with reference diagnosis, which was confirmed by two experienced pathologists at FDUSCC. All of the 184 samples were successfully analyzed, and no tumor specimens were excluded because of sample quality issues. In total, 151 samples were correctly predicted. The agreement rate was 82.1%. A Pearson Chi-square test shows that there is no difference between this study and the previous evaluation test performed by bioTheranostics Inc. No statistically significant decrease was observed in either the metastasis group or tumors with high grades. Conclusions: A comparable result with previous work was obtained. Specifically, specimens with a high probability score (>0.85) have a high chance (agreement rate = 95%) of being correctly predicted. No performance difference was observed between primary and metastatic specimens, and no difference was observed among three tumor grades. The use of laser capture micro-dissection (LCM) makes the THEROS CancerTYPE ID® accessible to almost all of the cancer patients with different tumor statuses. © 2012 Wu et al.
Source Title: PLoS ONE
ISSN: 19326203
DOI: 10.1371/journal.pone.0039320
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1371_journal_pone_0039320.pdf198.56 kBAdobe PDF



Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.